INCY - INCYTE CORP

99.13
-1.190   -1.200%

Share volume: 1,577,441
Last Updated: 05-12-2026
Business Services/Services – Research, Development, Testing Labs: -0.02%

PREVIOUS CLOSE
CHG
CHG%
$100.32
-1.19
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 0%
Dept financing 42%
Liquidity 75%
Performance 52%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.58%
1 Month
3.75%
3 Months
-1.95%
6 Months
-5.96%
1 Year
63.02%
2 Year
72.10%
Key data
Stock price
$99.13
P/E Ratio 
13.08
DAY RANGE
$98.94 - $101.24
EPS 
$7.29
52 WEEK RANGE
$61.10 - $112.29
52 WEEK CHANGE
$62.08
MARKET CAP 
18.731 B
YIELD 
N/A
SHARES OUTSTANDING 
199.782 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-29-2025
BETA 
0.75
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,196,372
AVERAGE 30 VOLUME 
$1,432,962
Company detail
CEO: Herve Hoppenot
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Recent news